Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

Annals of Oncology

Volumn 16, Issue 10, 2005, Pages 1569-1583

  Goldhirsch, Aron ^a,b   Glick, John H ^c   Gelber, Richard D ^d   Coates, Alan S ^e   Thürlimann, Beat ^f   Senn, H J ^g   Albain, Kathy S ^h   Bergh, Jonas ⁱ   Castiglione Gertsch, Monica ^j   Costa, Alberto ^k   Cuzick, Jack ^l   Davidson, Nancy ^m   Forbes, John F ⁿ   Goss, Paul ^o   Harris, Jay ^o   Howell, Anthony ^p   Ingle, James N ^q   Jakesz, Raimund ^r   Jassem, Jacek ^s   Kaufmann, Manfred ^t   Martin, Miguel ^u   Mauriac, Louis ^v   Morrow, Monica ^w   Mouridsen, Henning T ^x   Namer, Moise ^y   Piccart Gebhart, Martine J ^z   Possinger, Kurt ^aa   Pritchard, Kathleen ^ab   Rutgers, Emiel J T ^ac   Viale, Giuseppe ^ad   Wallgren, Arne ^ae   Wood, William C ^af   more..

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g Tumor Center ZeTuP   (Switzerland)

^h LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j International Breast Cancer Study Group Coordinating Center   (Switzerland)

^k IRCCS   (Italy)

^l UNIVERSITY OF LONDON   (United Kingdom)

^m JOHNS HOPKINS UNIVERSITY   (United States)

ⁿ UNIVERSITY OF NEWCASTLE   (Australia)

^o HARVARD MEDICAL SCHOOL   (United States)

^p CHRISTIE HOSPITAL   (United Kingdom)

^q MAYO CLINIC   (United States)

^r UNIVERSITY OF VIENNA   (Austria)

^s MEDICAL UNIVERSITY OF GDANSK   (Poland)

^t GOETHE UNIVERSITY   (Germany)

^u HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^v INSTITUT BERGONIÉ   (France)

^w NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^x Rigshospitalet   (Denmark)

^y CENTRE ANTOINE LACASSAGNE   (France)

^z JULES BORDET INSTITUTE   (Belgium)

^aa CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^ab DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^ac NETHERLANDS CANCER INSTITUTE   (Netherlands)

^ad UNIVERSITY OF MILAN   (Italy)

^ae SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^af EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GONADORELIN; GOSERELIN; LETROZOLE; METHOTREXATE; ONCOPROTEIN; PACLITAXEL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; UROKINASE;

ALGORITHM; AMENORRHEA; ARTHRALGIA; AXILLARY LYMPH NODE; BIOLOGICAL THERAPY; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; COST BENEFIT ANALYSIS; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DYSPAREUNIA; EARLY CANCER; ENDOCRINE SYSTEM; ENDOMETRIUM CANCER; ESTROGEN DEFICIENCY; FEMALE; FRACTURE; GENE OVEREXPRESSION; GYNECOLOGIC DISEASE; HORMONE RELEASE; HORMONE RESPONSE; HOT FLUSH; HUMAN; LIBIDO DISORDER; LOW DRUG DOSE; MASTECTOMY; MENOPAUSE; MYALGIA; ONCOGENE NEU; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; TERATOGENICITY; VAGINAL DRYNESS; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM;

EID: 27244436804     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi326     Document Type: Review

References (154)

1. Goldhirsch A, Wood WC, Gelber RD et al. Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer. J Clin Oncol 2003; 21: 3357-3365.
2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-488.
3. Thomson CS, Brewster DH, Dewar JA et al. Improvements in survival for women with breast cancer in Scotland between 1987 and 1993: Impact of earlier diagnosis and changes in treatment. Eur J Cancer 2004; 40: 743-753.
4. Martino S, Cauley JA, Barrett-Connor E et al. Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomised trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-1761.
5. Goss PE, Strasser-Weippl K. Prevention strategies with aromatase inhibitors. Clin Cancer Res 2004; 10: 372-379.
6. Garber J. Genetic counseling: Therapeutic consequences. Breast 2005; 14 (Suppl): S3.
7. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
8. Foulkes WD, Brunet JS, Stefansson IM et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/ glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004; 64: 830-835.
9. Kriege M, Brekelmans CT, Boetes C et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 427-437.
10. Rebbeck TR, Lynch HT, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-1622.
11. Schwartz MD, Kaufman E, Peshkin BN et al. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 2003; 21: 4034-4041.
12. Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 2004; 22: 1055-1062.
13. Garber J, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005; 23: 276-292.
14. Tassone P, Tagliaferri P, Perricelli A et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003; 88: 1285-1291.
15. Borg A. The biology of BRCA1/2 and beyond. Breast 2005; 14 (Suppl): S5.
16. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
17. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004; 23: 7274-7282.
18. Minn AJ, Kang Y, Serganova I et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005; 115: 44-55.
19. Klijn JG, Blamey RW, Boccardo F et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomised trials. J Clin Oncol 2001; 19: 343-353.
20. Dowsett M. The biology of steroid hormones and endocrine therapies. Breast 2005; 14 (Suppl): S5.
21. Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/ HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-935.
22. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomised trial. J Clin Oncol 2001; 19: 3808-3816.
23. Lipton A, Ali SM, Leitzel K et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003; 21: 1967-1972.
24. Osborne CK. Endocrine responsiveness: Understanding how progesterone receptor can be used to select endocrine therapy. Breast 2005; 14 (Suppl): S5.
25. van de Vijver MJ. Biological variables and prognosis of DCIS. Breast 2005; 14 (Suppl): S7.
26. Cornfield DB, Palazzo JP, Schwartz GF et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: A study of a large cohort of patients treated with surgery alone. Cancer 2004; 100: 2317-2327.
27. Roka S, Rudas M, Taucher S et al. High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur J Surg Oncol 2004; 30: 243-247.
28. Ceilley E, Jagsi R, Goldberg S et al. The management of ductal carcinoma in situ in North America and Europe. Results of a survey. Cancer 2004; 101: 1958-1967.
29. Veronesi P, Intra M, Vento AR et al. Sentinel lymph nodes for localized DCIS? Breast 2005; 14 (Suppl): S7.
30. Viale G. Histopathology of primary breast cancer 2005. Breast 2005; 14 (Suppl): S6.
31. Cserni G, Gregori D, Merletti F et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg 2004; 91: 1245-1252.
32. Colleoni M, Rotmensz N, Perruzzotti G et al. Size of breast cancer metastases in axillary lymph nodes: Clinical relevance of minimal lymph node involvement. J Clin Oncol 2005; 23: 1379-1389.
33. Hayes D. Prognostic and predictive factors revisited. Breast 2005; 14 (Suppl): S6.
34. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: A study of preoperative treatment. Clin Cancer Res 2004; 10: 6622-6628.
35. Naume B, Wiedswang G, Borgen E et al. The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: Evaluation of morphologic categories and the number of clinically significant cells. Clin Cancer Res 2004; 10: 3091-3097.
36. Wiedswang G, Borgen E, Kareson R et al. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavourable clinical outcome. Clin Cancer Res 2004; 10: 5342-5348.
37. Harbeck N, Kates RE, Schmitt M et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 2004; 5: 348-352.
38. Harbeck N. Pooled analysis validates predictive impact of uPA and PAI-1 for response to adjuvant chemotherapy in breast cancer. Breast 2005; 14 (Suppl): S27.
39. Norberg T, Klaar S, Karf G et al. Increased p53 mutation frequency during tumor progression - results from a breast cancer cohort. Cancer Res 2001; 61: 8317-8321.
40. Poelman SM, Heimann R, Fleming GF et al. Invariant p53 immunostaining in primary and recurrent breast cancer. Eur J Cancer 2004; 40: 28-32.
41. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
42. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-10398.
43. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
44. Kaufmann M. Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast 2005; 14 (Suppl): S11.
45. Chen AM, Meric-Bernstam F, Hunt KK et al. Breast conservation after neoadjuvant chemotherapy: The MD Anderson cancer center experience. J Clin Oncol 2004; 22: 2303-2312.
46. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-3685.
47. Dixon JM. Role of endocrine therapy in the neoadjuvant surgical setting. Ann Surg Oncol 2004; 11: 18-23.
48. Semiglazov VF, Semiglazov V, Ivanov V et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER-positive breast cancer. J Clin Oncol 2004; 23: 7.
49. Morrow M. Limiting breast surgery to the proper minimum. Breast 2005; 14 (Suppl): S7-S8.
50. Petit JY. Nipple sparing mastectomy in association with intraoperative radiotherapy: A new type of mastectomy for breast cancer treatment. Breast 2005; 14 (Suppl): S8.
51. Bellon J, Harris J. Which extent of adjuvant radiotherapy is standard? Breast 2005; 14 (Suppl): S8-S9.
52. Hughes KS, Schnaper LA, Berry D et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004; 351: 971-977.
53. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with 4 or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b & c randomized trials. ESTRO 2004, Amsterdam (Abstr 33). (http://www.estroweb.org/ESTRO/upload/abstractbooks/ 2AbstractbookESTRO23.pdf Available on August 20th. 2005).
54. Ragaz J, Olivotto IA, Spinelli JJ et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005; 97: 116-126.
55. Wallner P, Arthur D, Bartelink H et al. Workshop on partial breast irradiation: State of the art and the science, Bethesda, MD, December 8-10, 20o2. J Natl Cancer Inst 2004; 96: 175-184.
56. Orecchia R. Intraoperative radiation therapy to the breast. Breast 2005; 14 (Suppl): S8.
57. Huang J, Barbera L, Brouwers M et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol 2003; 21: 555-563.
58. Baselga J, Gianni L, Geyer C et al. Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol 2004; 31: 51-57.
59. Disis ML, Salazar LG, Knutson KL. Peptide-based vaccines in breast cancer. Breast Dis 2004; 20: 3-11.
60. Ropero S, Menendez JA, Vazquez-Martin A et al. Trastuzumab plus tamoxifen, anti-proliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat 2004; 86: 125-137.
61. Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10: 5650-5655.
62. Burstein HJ, Harris LN, Gelman R et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003; 21: 46-53.
63. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
64. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423-436.
65. Orlando L, Colleoni M, Bertolini F et al. Metronomic oral chemotherapy (CT) versus the same regimen in association with Thalidomide (TLM): Results of a randomised trial in patients (pts) with advanced breast cancer (ABC). J Clin Oncol 2004; 22: 3015 (Abstr).
66. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
67. International Breast Cancer Study Group (IBCSG), on behalf of the Breast International Group (BIG). Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: A prospective randomised double-blind phase III study. The Primary Therapy of Early Breast Cancer 9th International Conference in St Gallen, Switzerland, 26 January 2005. Also available as: Thurlimann BJ, Keshaviah A, Mouridsen H et al. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer (Abstract). J Clin Oncol (Annual Meeting Proceedings) 23: 511, 2005.
68. Coombes RC, Hall E, Gibson LJ et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
69. Jakesz R, Kaufmann M, Gnant M et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results front 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004; 88: 7.
70. Goss PE. The rise and current status of aromatase inhibitors in breast cancer treatment. Breast Cancer Res Treat 2004; 88: 1.
71. Castiglione-Gertsch M. Adjuvant endocrine therapies for postmenopausal women: Standards and not. Breast 2005; 14 (Suppl): S9.
72. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005; 23: 619-629.
73. Ravdin PM, Davis GJ. A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen. Clin Breast Cancer 2004; 5: 313-316.
74. Pritchard K. Adjuvant endocrine therapies for pre/perimenopausal women. Breast 2005; 14 (Suppl): S9.
75. Dellapasqua S, Colleoni M, Gelber RD et al. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol 2005; 23: 1736-1750.
76. Colleoni M, Gelber S, Snyder R et al. Randomized comparison of adjuvant tamoxifen (Tam) versus no hormonal treatment for premenopausal women with node-positive (N+), early stage breast cancer: First results of International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2004; 22: 532 (Abstr).
77. Fallowfield L. Acceptance of adjuvant endocrine therapies and quality of life issues. Breast 2005; 14 (Suppl): S13.
78. Albain KS, Green SJ, Ravdin PM et al. for SWOG, ECOG, CALGB, NCCTG and NCIC-CTG: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from Intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 2002; 21: 37a.
79. Albain K, Barlow W, O'Malley F et al. Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (INT-0100, SWOG-8814): Concurrent (CAFT) vs sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) vs T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone PgR receptor-positive breast cancer. Proc SABCS 2004 (Abstr37). (http://www.abstracts2view.com/sabcs/sessionindex.php Available on August 20th, 2005).
80. Albain KS. Do all patients with endocrine-responsive early breast cancer need adjuvant chemotherapy before endocrine treatment? Breast 2005; 14 (Suppl): S9-S10.
81. Berry DA, Cirrincione C, Henderson IC et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive breast cancer: 20-year experience of the CALGB & U.S. Breast Intergroup. Breast Cancer Res Treat 2004; 88: 17.
82. Gelber RD, Goldhirsch A. Predicting response to systemic treatments: learning from the past to plan for the future. Breast 2005; 14 (Suppl): S11.
83. Aebi S. Special issues related to adjuvant therapy in very young women. Breast 2005; 14 (Suppl): S12.
84. Goldhirsch A, Gelber RD, Yothers G et al. Adjuvant therapy for very young women with breast cancer: Need for tailored treatments. J Natl Cancer Inst Monogr 2001; 30: 44-51.
85. Muss H. Special issues related to adjuvant therapy in elderly women. Breast 2005; 14 (Suppl): S12-S13.
86. Crivellari D, Price K, Gelber RD et al. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. J Clin Oncol 2003; 21: 4517-4523.
87. Fargeot P, Bonneterre J, Roche H et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol 2004; 22: 4622-4630.
88. Biganzoli L, Aapro M, Balducci L et al. Adjuvant therapy in elderly patients with breast cancer. Clin Breast Cancer 2004; 5: 188-195.
89. Winer EP. Standards of follow-up for primary breast cancer. Breast 2005; 14 (Suppl): S6-S7.
90. Rutgers EJ. Follow-up care in breast cancer. Expert Rev Anticancer Ther 2004; 4: 212-218.
91. Meijer-van Gelder ME, Look MP, Peters HA et al. Urokinase-type plasminogen activator system in breast cancer: Association with tamoxifen therapy in recurrent disease. Cancer Res 2004; 64: 4563-4568
92. Coates A, Goldhirsch A, Gelber R, International Breast Cancer Study Group. Overhauling the breast cancer overview: Are subsets subversive? Lancet Oncol 2002; 3: 525-526.
93. Colleoni M, Gelber S, Coates AS et al. for the International Breast Cancer Study Group. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 2001; 19: 4141-4149.
94. Allred DC, Harvey JM, Berardo M et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathol 1998; 11: 155-168.
95. Harvey JM, Clark GM, Osborne CK et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
96. Cody HS 3rd, Borgen PI, Tan LK. Redefining prognosis in node-negative breast cancer: Can sentinel lymph node biopsy raise the threshold for systemic adjuvant therapy? Ann Surg Oncol 2004; 11: 227-230.
97. Bofin AM, Ytterhus B, Martin C et al. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 2004; 122: 110-119.
98. Wood WC, Anderson M, Lyles RH et al. Can we select which patients with small breast cancers should receive adjuvant chemotherapy? Ann Surg 2002; 235: 859-862.
99. Colleoni M, Rotmensz N, Peruzzotti G et al. Minimal and small size invasive breast cancer with no axillary lymph node involvement: The need for tailored adjuvant therapies. Ann Oncol 2004; 15: 1633-1639.
100. Cufer T, Piccart-Gebhart M. Adjuvant chemotherapy: Standards and beyond. Breast 2005; 14 (Suppl): S3-S4.
101. Ross JS, Fletcher JA, Linette GP et al. The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist 2003; 8: 307-325.
102. Konecny GE, Thomssen C, Luck HJ et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004; 96: 1141-1151.
103. Pinder SE, Ellis IO, Galea M et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: Relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 1994; 24: 41-47.
104. Kato T, Kameoka S, Kimura T et al. The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer. Br J Cancer 2003; 88: 1900-1908.
105. Hasebe T, Sasaki S, Imoto S et al. Histological characteristics of tumor in vessels and lymph nodes are significant predictors of progression of invasive ductal carcinoma of the breast: A prospective study. Hum Pathol 2004; 35: 298-308.
106. Schoppmann SF, Bayer G, Aumayr K et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004; 240: 306-312.
107. de Mascarel I, Bonichon F, Durand M et al. Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer 1998; 34: 58-65.
108. Adjuvant! Online. http://www.adjuvantonline.com/ (August 20th, 2005; date last accessed).
109. Mayo Clinic. http://www.mayoclinic.com/calcs/ The "adjuvant systemic therapy for breast cancer" tool has been removed indefinitely after January 2005 (St. Gallen Conference) due to the availability of adjuvantonline.
110. Olivotto IA, Bajdik C, Ravdin PM et al. An independent population-based validation of the adjuvant decision-aid for stage I-II breast cancer. J Clin Oncol 2004; 22 (Suppl); 522.
111. Falkson G, Falkson HC. CAF and nasal buserelin in the treatment of premenopausal women with metastatic breast cancer. Eur J Cancer Clin Oncol 1989; 25: 737-741.
112. Torrisi R, Colleoni M, Magni E et al. Endocrine and chemoendocrine primary therapy in premenopausal women with endocrine responsive breast cancer: A feasibility study. Breast Cancer Res Treat 2004; 88: 110-111.
113. Colleoni M, Li S, Gelber RD et al. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol 2005; 16: 716-725.
114. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998; 351: 1451-1467.
115. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 1996; 348: 1189-1196.
116. Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 2001; 30: 67-71.
117. Prowell TM, Davidson NE. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? Oncologist 2004; 9: 507-517.
118. International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 2003; 95: 1833-1846.
119. Barthelmes L, Gateley CA. Tamoxifen and pregnancy. Breast 2004; 13: 446-451.
120. Love RR, Duc NB, Havighurst TC et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 2003; 21: 453-457.
121. Arriagada R, Le MG, Spielmann M et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 2005; 16: 389-396.
122. Goss PE, Ingle JN, Martino S et al. A randomised trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
123. Boccardo F, Rubagotti A, Amoroso D et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study. J Clin Oncol 2001; 19: 4209-4215.
124. Boccardo F, Rubagotti A, Amoroso D et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003; 82: 6-7.
125. Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 2004; 101: 1311-1322.
126. Carlson RW, Anderson BO, Chopra R et al. Treatment of breast cancer in countries with limited resources. Breast J 2003; 9: 67-74.
127. Fisher B, Jeong JH, Anderson S et al. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: Updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 2004; 96: 1823-1831.
128. Bonadonna G, Moliterni A, Zambetti M et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ 2005; 330: 217.
129. Cameron DA, Anderson A, Toy E et al. Block sequential adriamycin CMF - optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer? Br J Cancer 2002; 87: 1365-1369.
130. Therasse P, Mauriac L, Welnicka-Jaskiewicz M et al. Final results of a randomised phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003; 21: 843-850.
131. Bull JM, Tormey DC, Li SH et al. A randomised comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 1978; 41: 1649-1657.
132. Guidi AJ, Berry DA, Broadwater G et al. Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: A Cancer and Leukemia Group B correlative science study from protocols 8541/8869. J Clin Oncol 2002; 20: 732-742.
133. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
134. Roché H, Fumoleau P, Spielmann M et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Breast Cancer Res Treat 2004; 88: 27.
135. Bergh J, Wiklund T, Erikstein B et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000; 356: 1384-1391.
136. Bonneterre J, Roche H, Kerbrat P et al. Long-term cardiac follow-up in relapse free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 2004; 22: 3070-3079.
137. Martin M, Pienkoswki T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-2313.
138. Colleoni M, Bonetti M, Coates AS et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol 2000; 18: 584-590.
139. Lamb D, Atkinson C, Joseph D et al. Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer. Australas Radiol 1999; 43: 220-226.
140. Bellon JR, Shulman LN, Come SE et al. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma. Cancer 2004; 100: 1358-1364.
141. Ahn PH, Vu HT, Lannin D et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 2005; 23: 17-23.
142. Harris EE, Christensen VJ, Hwang WT et al. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol 2005; 23: 11-16.
143. Harris EE, Solin LJ. Treatment of early-stage breast cancer in elderly women. Med Pediatr Oncol 2000; 34: 48-52.
144. Fyles AW, McCready DR, Manchul LA et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004; 351: 963-970.
145. Bartelink H, Horiot JC, Poortmans P et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001; 345: 1378-1387.
146. Troung MT, Hirsch AE, Formenti SC. Novel approaches to postoperative radiation therapy as part of breast-conserving therapy for early-stage breast cancer. Clin Breast Cancer 2003; 4: 253-263.
147. Remouchamps VM, Vicini FA, Sharpe MB et al. Significant reductions in heart and lung doses using deep inspiration breath hold with active breathing control and intensity-modulated radiation therapy for patients treated with locoregional breast irradiation. Int J Radiat Oncol Biol Phys 2003; 55: 392-406.
148. Pedersen AN, Korreman S, Nystrom H et al. Breathing adapted radiotherapy of breast cancer: Reduction of cardiac and pulmonary doses using voluntary inspiration breath-hold. Radiother Oncol 2004; 72: 53-60.
149. Hurny C, Bernhard J, Coates AS et al. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet 1996; 347: 1279-1284.
150. Fallowfield L, McGurk R, Dixon M. Same gain, less pain: Potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer. Eur J Cancer 2004; 40: 2403-2410.
151. Studts JL, Abell TD, Roetzer LM et al. Preferences for different methods of communicating information regarding adjuvant chemotherapy for breast cancer. Psychooncology 2005; 14: 647-660.
152. Duric V, Stockler M. Patients' preferences for adjuvant chemotherapy in early breast cancer: A review of what makes it worthwile. Lancet Oncol 2001; 2: 691-697.
153. Schover LR. Myth-busters: Telling the true story of breast cancer survivorship. J Natl Cancer Inst 2004; 96: 1800-1801.
154. Simon MS, Du W, Flaherty L et al. Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 2004; 22: 2046-2052.